Company news
Theralase Technologies Inc. (TSXV:TLT) news
Theralase Technologies Inc. news releases on 6ix. Latest, May 30, 2023: Theralase(R) Releases 1Q2023 Interim Financial Statements
Press releases — page 3
Theralase(R) Releases 1Q2023 Interim Financial Statements
May 30, 2023
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
May 24, 2023
Theralase Provides Update on Phase II Bladder Cancer Study
May 10, 2023
TSX Venture Exchange Stock Maintenance Bulletins
January 5, 2023
Theralase Release FY2020 Audited Financial Statements
April 28, 2021
Theralase(R) Releases Quarterly Newsletter
April 27, 2021
Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
April 9, 2021
Theralase Launches Anti-Cancer Therapy Research Centre
March 29, 2021
Theralase Launches Sixth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
March 25, 2021
Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
February 24, 2021
Theralase Launches Fourth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
January 27, 2021
Theralase Launches Third Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
January 25, 2021
Theralase Expands Intellectual Property Portfolio
January 22, 2021
Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
January 20, 2021
Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
January 19, 2021
Theralase Announces Warrant Extension
January 8, 2021
University of British Columbia Launched as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
December 7, 2020
CORRECTION: Theralase Releases 3Q2020 Financial Statements
November 27, 2020
Theralase Release 3Q2020 Financial Statements
November 27, 2020
Theralase Granted FDA Fast Track Designation for NMIBC Phase II Clinical Study
November 23, 2020
IIROC Trading Resumption - TLT
November 13, 2020
Theralase Technology Demonstrates High Kill Rate of Coronavirus (BSL-2)
November 13, 2020
IIROC Trading Halt - TLT
November 13, 2020
Theralase Releases Quarterly Newsletter
October 26, 2020
Theralase Provides Update on Bladder Cancer Study
September 24, 2020
Theralase Provides Update on Voting Procedures for Shareholder Meeting
September 24, 2020
Theralase Release 2Q2020 Financial Statements
August 28, 2020
Theralase Amends the Company's Standard By-Laws
August 19, 2020
Theralase Signs Agreement with University of Manitoba to Commence Development of Coronavirus Vaccine and Therapy
August 19, 2020
Canadian Clinical Study Sites Re-Commence Bladder Cancer Study
August 12, 2020
Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study ("Study II") Progress
July 30, 2020
Theralase Announces Management Information Circular and Annual General Meeting Postponement Due to COVID-19
June 30, 2020
Theralase Release 1Q2020 Financial Statements
May 29, 2020
Theralase Receives FDA IND Authorization
May 19, 2020
Theralase Releases 2019 Financial Results
April 29, 2020
Theralase Provides Company Update on Phase II Bladder Cancer Clinical Study
March 20, 2020
Theralase Advances Its Pivotal Phase II Non-Muscle Invasive Bladder Cancer Study with a New Clinical Study Site in Nova Scotia
February 25, 2020
Theralase Technologies Awarded 2020 TSX Venture 50
February 20, 2020
Theralase Granted US Patent for Multiwavelength Photodynamic Therapy
January 27, 2020
Theralase Wins Precedent-Setting Lawsuit Against Anonymous Individuals for Posting Defamatory Comments Online
January 16, 2020
View from the C-Suite: Shawn Shirazi, Chief Executive Officer, Theralase Technologies Inc., tells his company's story. Filmed on December 18, 2019
January 8, 2020
Theralase Releases Third Quarter 2019 Financial Results and Company Update
November 29, 2019
Theralase Researchers Receive Recognition for Recent Scientific Publications
November 27, 2019
Theralase Announces Leadership Transition
October 31, 2019
Theralase Granted European Patent for Anti-Cancer Photo Dynamic Compounds
October 22, 2019
London Health Sciences Centre Launches as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
October 7, 2019
Theralase Files Investigational New Drug Application with the FDA
October 1, 2019
Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment
September 30, 2019
Theralase Grants Stock Options
September 16, 2019
Theralase Annouces First Patient Treated in Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
September 4, 2019